60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP Ā· Real-Time Price Ā· USD
0.4682
-0.0318 (-6.36%)
At close: Nov 20, 2026, 4:00 PM EST
0.5077
+0.0395 (8.44%)
After-hours: Nov 20, 2026, 5:31 PM EST
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $233.24K in the quarter ending September 30, 2026, a decrease of -55.87%. This brings the company's total for the last twelve months to $919.60K, down -32.63% year-over-year. In the year 2025, 60 Degrees Pharmaceuticals had annual revenue of $1.41M with 106.81% growth. That makes 60 Degrees Pharmaceuticals the 43,757th largest company in the world by revenue and 6,136th in the United States.
Revenue (ttm)
$919.60K
Revenue Growth
-32.63%
P/S Ratio
1.79
Revenue / Employee
$306,535
Employees
3
Market Cap
1.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.41M | 727.75K | 106.81% |
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.76M |
| Decoy Therapeutics | 535.06K |
| BioRestorative Therapies | 357.87K |
| Jupiter Neurosciences | 78.64K |
| Senti Biosciences Holdings | 74.00K |
SXTP News
- 6 days ago - 60 Degrees Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 11 days ago - 60 Degrees Pharmaceuticals Transcript: Investor update - Transcripts
- 24 days ago - 60 Degrees expands vector-borne disease research portfolio with USM - TheFly
- 25 days ago - 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome - GlobeNewsWire
- 25 days ago - 60 Degreesā tafenoquine shows improvement in all five babesiosis patients - TheFly
- 26 days ago - 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Slides: Investor presentation - Filings
- 6 weeks ago - 60 Degrees Pharmaceuticals Transcript: Study update - Transcripts